Active Smallcap & Microcap Investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CYCA News: Cytta Corp. Announces Additional Purchase Orders for CyttaCOMMS from Multiple Florida Police Departments
Over 80 Police Departments Now Conducting Live Operational Trials With Cytta COMMS 3.0 Streaming Software
LAS VEGAS, NV / ACCESSWIRE / August 16, 2024 / Cytta Corp. (OTCQB:CYCA), a leader in real-time communication and data streaming solutions, is thrilled to announce a major breakthrough with the signing of new purchase orders for CyttaCOMMS from five additional Florida police departments: Winter Haven PD, Zephyrhills PD, North Port PD, Sanford PD, and Ocala PD. This incredible momentum, over the last two months, brings our total to 10 police departments, now harnessing the power of CyttaCOMMS 3.0. These results from the 80+ agencies currently in free trials, is a testament to our transformative impact on law enforcement operations
The extraordinary adoption rate of CyttaCOMMS 3.0 after their free trial, is a game-changer for bringing Cytta's technology to public safety. Our technology is redefining how police departments communicate and respond to emergencies, providing them with secure, real-time video and data streaming that dramatically improves situational awareness and operational effectiveness. The enthusiasm among these departments is palpable, as they recognize the life-saving potential of integrating CyttaCOMMS into their daily operations.
"We couldn't be more excited about the positive feedback we're receiving from the departments that have already implemented CyttaCOMMS," said Mike Elliott, VP of Business Development at Cytta Corp. "They're experiencing firsthand how our technology enhances their ability to protect and serve their communities. This excitement fuels our commitment to delivering unparalleled support to our new customers, ensuring they maximize the benefits of CyttaCOMMS in every situation."
But the excitement doesn't stop there. Cytta Corp. is also celebrating a successful national advertising campaign for CyttaAIR, our cutting-edge integrated drone hardware and software solutions. The response has been overwhelming, with commercial drone pilots from coast to coast registering for free trials. This wave of interest underscores the industry's recognition of CyttaAIR as a revolutionary tool for secure, real-time video streaming in drone operations. The market's reaction further validates Cytta Corp.'s position as a leader in both public safety technology and the broader drone industry.
As CyttaCOMMS and CyttaAIR continue to gain traction, investors can take confidence in Cytta Corp.'s robust growth trajectory and the significant market opportunities ahead. The expanding adoption of our solutions by law enforcement and commercial operators alike signals a bright future, filled with innovation and success.
About Cytta Corp
Cytta Corp (OTCQB:CYCA) is at the cutting edge of video streaming and communication solutions, driving innovation to enhance operational efficiency and public safety. Our flagship product, CyttaCOMMS, ensures secure, real-time video streaming across any drone brand, providing seamless integration and heightened situational awareness for law enforcement and emergency responders. Cytta's innovative new product, CyttaCARES, is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
For more information about Cytta Corp and our groundbreaking technology solutions, please visit www.cytta.com.
Contact Us
Cytta Corp.
Toll free # : 1 877 CYTTAUS (298 8287)
Call Local : 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Natalia Sokolova, President & COO
Direct: (424) 333-0595 (or message)
Natalia@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708.
SOURCE: Cytta Corp.
$CYCA News: Cytta Corp. Announces Additional Purchase Orders for CyttaCOMMS from Multiple Florida Police Departments
Over 80 Police Departments Now Conducting Live Operational Trials With Cytta COMMS 3.0 Streaming Software
LAS VEGAS, NV / ACCESSWIRE / August 16, 2024 / Cytta Corp. (OTCQB:CYCA), a leader in real-time communication and data streaming solutions, is thrilled to announce a major breakthrough with the signing of new purchase orders for CyttaCOMMS from five additional Florida police departments: Winter Haven PD, Zephyrhills PD, North Port PD, Sanford PD, and Ocala PD. This incredible momentum, over the last two months, brings our total to 10 police departments, now harnessing the power of CyttaCOMMS 3.0. These results from the 80+ agencies currently in free trials, is a testament to our transformative impact on law enforcement operations
The extraordinary adoption rate of CyttaCOMMS 3.0 after their free trial, is a game-changer for bringing Cytta's technology to public safety. Our technology is redefining how police departments communicate and respond to emergencies, providing them with secure, real-time video and data streaming that dramatically improves situational awareness and operational effectiveness. The enthusiasm among these departments is palpable, as they recognize the life-saving potential of integrating CyttaCOMMS into their daily operations.
"We couldn't be more excited about the positive feedback we're receiving from the departments that have already implemented CyttaCOMMS," said Mike Elliott, VP of Business Development at Cytta Corp. "They're experiencing firsthand how our technology enhances their ability to protect and serve their communities. This excitement fuels our commitment to delivering unparalleled support to our new customers, ensuring they maximize the benefits of CyttaCOMMS in every situation."
But the excitement doesn't stop there. Cytta Corp. is also celebrating a successful national advertising campaign for CyttaAIR, our cutting-edge integrated drone hardware and software solutions. The response has been overwhelming, with commercial drone pilots from coast to coast registering for free trials. This wave of interest underscores the industry's recognition of CyttaAIR as a revolutionary tool for secure, real-time video streaming in drone operations. The market's reaction further validates Cytta Corp.'s position as a leader in both public safety technology and the broader drone industry.
As CyttaCOMMS and CyttaAIR continue to gain traction, investors can take confidence in Cytta Corp.'s robust growth trajectory and the significant market opportunities ahead. The expanding adoption of our solutions by law enforcement and commercial operators alike signals a bright future, filled with innovation and success.
About Cytta Corp
Cytta Corp (OTCQB:CYCA) is at the cutting edge of video streaming and communication solutions, driving innovation to enhance operational efficiency and public safety. Our flagship product, CyttaCOMMS, ensures secure, real-time video streaming across any drone brand, providing seamless integration and heightened situational awareness for law enforcement and emergency responders. Cytta's innovative new product, CyttaCARES, is a game-changer in ensuring the safety and well-being of children in educational institutions and beyond. CyttaAIR, a groundbreaking platform designed to innovate and consolidate the best of drone hardware, software, and resources for Federal and State Law Enforcement Agencies. Cytta's CyttaCOMP ISTAR (Intelligence, Surveillance, Target Acquisition and Reconnaissance) technology delivers real-time compression of video streams with ultra-low latency.
For more information about Cytta Corp and our groundbreaking technology solutions, please visit www.cytta.com.
Contact Us
Cytta Corp.
Toll free # : 1 877 CYTTAUS (298 8287)
Call Local : 1 740 CYTTAUS (298 8287)
http://www.cytta.com
info@cytta.com
Gary Campbell, CEO
Direct (702) 900-7022 (or message)
Gary@cytta.com
Natalia Sokolova, President & COO
Direct: (424) 333-0595 (or message)
Natalia@cytta.com
Mike Elliott, VP of Business Development
mikeelliott@cytta.com
(689) 222-8708.
SOURCE: Cytta Corp.
$IDVV News: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
$IDVV News: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
$SHOT News: Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights
- Q2 Revenues Increased 40%
- Q2 Operating Expenses Decreased 17.7%
- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content
- Revolutionary Formula to be Soon Released in Convenient 4-ounce Bottles
- Powdered Version of Alcohol-reducing Nutraceutical to be Released in Q4
JUPITER, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the Company) the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, has released its financial results for its second quarter ended June 30, 2024 as well as a corporate highlights for the quarter.
"We are very excited about our financial performance and our achievements for the second quarter of 2024. A dramatic increase in our revenues with a dramatic decrease in our operating expenses only showcases Safety Shot’s determination to bring value to stakeholders,” stated CEO Jarrett Boon. “We have exciting things expected in the next couple of quarters and believe they will serve as catalysts to further strengthen the company’s financial results going forward. As we continue to execute our business strategy, we remain focused on enhancing our growth potential. This is illustrated by the promising clinical results the company reported this month as well as new partnerships and new product lines the company will be launching in the near future.”
Second Quarter 2024 Highlights:
Company reports a 40% increase in sales in the second quarter compared to the first quarter.
Company reports a 17.7% decrease in operating expenses in the second quarter compared to the first quarter, highlighting significant progress in Safety Shot’s financial health.
Company reveals significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC. Within 30 minutes of consuming Safety Shot, participants showed a 30%-50% faster rate of alcohol reduction compared to the placebo group. Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is now clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
Company is advancing several product formats and formulations to continue to offer a wide array of products that can be purchased at various locations that coincide with consumer shopping habits.
Company announced that its revolutionary formula will be released in new, convenient 4-ounce bottles. Designed for easy on-the-go use, this new format ensures that customers can enjoy the benefits of Safety Shot's groundbreaking formula anytime, anywhere. The 4-ounce bottles are anticipated to launch in Q3.
Company’s R&D team has successfully found a powdered solution that maintains 100% of the efficacy of the world’s first alcohol-reducing product. Safety Shot will offer a convenient stick pack in Q4.
Company announced a partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.
Company announced a strategic partnership with Mr. Checkout, a national network of independent distributors, full-line grocery distributors, and wagon-jobbers. This partnership marks a significant milestone in Safety Shot's mission to provide a revolutionary solution for responsible alcohol consumption to the masses. Additional partnerships include GoPuff, BevMo, and more.
About Safety Shot, Inc.
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
Media and Investor Contact:
Autumn Communications
Jess Weinberger
Phone: 201-213-3239
Email: shot@autumncommunications.com
Investor Relations
Medon Michaelides
Phone: 561-244-7100
Email: investors@drinksafetyshot.com
https://www.globenewswire.com/newsroom/ti?nf=OTIwNjE3NCM2NDI3Njg3IzUwMDExNzExOA==
https://ml.globenewswire.com/media/YzBjY2FmNDAtMzk3My00YTg1LWIxZTYtNzc2MmNmNTM2MTMwLTUwMDExNzExOA==/tiny/Safety-Shot-Inc-.png
Source: Safety Shot, Inc.
$SHOT News: Safety Shot Releases Second Quarter 2024 Results and Corporate Highlights
- Q2 Revenues Increased 40%
- Q2 Operating Expenses Decreased 17.7%
- Recent Clinical Trial Confirms Dramatic Reduction of Blood Alcohol Content
- Revolutionary Formula to be Soon Released in Convenient 4-ounce Bottles
- Powdered Version of Alcohol-reducing Nutraceutical to be Released in Q4
JUPITER, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the Company) the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, has released its financial results for its second quarter ended June 30, 2024 as well as a corporate highlights for the quarter.
"We are very excited about our financial performance and our achievements for the second quarter of 2024. A dramatic increase in our revenues with a dramatic decrease in our operating expenses only showcases Safety Shot’s determination to bring value to stakeholders,” stated CEO Jarrett Boon. “We have exciting things expected in the next couple of quarters and believe they will serve as catalysts to further strengthen the company’s financial results going forward. As we continue to execute our business strategy, we remain focused on enhancing our growth potential. This is illustrated by the promising clinical results the company reported this month as well as new partnerships and new product lines the company will be launching in the near future.”
Second Quarter 2024 Highlights:
Company reports a 40% increase in sales in the second quarter compared to the first quarter.
Company reports a 17.7% decrease in operating expenses in the second quarter compared to the first quarter, highlighting significant progress in Safety Shot’s financial health.
Company reveals significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC. Within 30 minutes of consuming Safety Shot, participants showed a 30%-50% faster rate of alcohol reduction compared to the placebo group. Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is now clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
Company is advancing several product formats and formulations to continue to offer a wide array of products that can be purchased at various locations that coincide with consumer shopping habits.
Company announced that its revolutionary formula will be released in new, convenient 4-ounce bottles. Designed for easy on-the-go use, this new format ensures that customers can enjoy the benefits of Safety Shot's groundbreaking formula anytime, anywhere. The 4-ounce bottles are anticipated to launch in Q3.
Company’s R&D team has successfully found a powdered solution that maintains 100% of the efficacy of the world’s first alcohol-reducing product. Safety Shot will offer a convenient stick pack in Q4.
Company announced a partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.
Company announced a strategic partnership with Mr. Checkout, a national network of independent distributors, full-line grocery distributors, and wagon-jobbers. This partnership marks a significant milestone in Safety Shot's mission to provide a revolutionary solution for responsible alcohol consumption to the masses. Additional partnerships include GoPuff, BevMo, and more.
About Safety Shot, Inc.
Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled “Risk Factors” in Safety Shot’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
Media and Investor Contact:
Autumn Communications
Jess Weinberger
Phone: 201-213-3239
Email: shot@autumncommunications.com
Investor Relations
Medon Michaelides
Phone: 561-244-7100
Email: investors@drinksafetyshot.com
https://www.globenewswire.com/newsroom/ti?nf=OTIwNjE3NCM2NDI3Njg3IzUwMDExNzExOA==
https://ml.globenewswire.com/media/YzBjY2FmNDAtMzk3My00YTg1LWIxZTYtNzc2MmNmNTM2MTMwLTUwMDExNzExOA==/tiny/Safety-Shot-Inc-.png
Source: Safety Shot, Inc.
$CETX News: Cemtrex Reports Third Quarter 2024 Financial Results
Q3’24 Industrial Services Segment Revenue Increased 49% to $8.5M
News Link:
https://finance.yahoo.com/news/cemtrex-reports-third-quarter-2024-201000128.html
Hauppauge, NY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its unaudited financial and operational results for the fiscal third quarter ended June 30, 2024.
Key Third Quarter FY 2024 and Subsequent Highlights
Revenue for Q3’24 was flat at $14.7 million, compared to revenue of $14.7 million for Q3’23. Security segment revenues decreased 31% to $6.2 million in Q3’24 due primarily to the delay of multiple projects for the segment’s products and services.Industrial Services segment revenues for Q3’24 increased 49% to $8.5 million, on increased demand and additional revenue from the Heisey Mechanical acquisition completed in Q4’23.
Revenue for the nine months ended June 30, 2024 increased 14% to $48.7 million, compared to revenue in the prior year period of $42.8 million. Security segment revenues for the nine months ended June 30, 2024, decreased 10% to $23.4 million compared to $25.9 million for the nine months ended June 30, 2023.Industrial Services segment revenues for the nine months ended June 30, 2024, increased 50% to $25.3 million compared to $16.8 million for the nine months ended June 30, 2023.
Closed $10 million upsized underwritten public offering to conduct operations, increase marketing efforts, invest in existing business initiatives and products, and for the partial repayment of indebtedness.
Cash, cash equivalents and restricted cash as of June 30, 2024 was $7.6 million, compared to $6.3 million as of September 30, 2023.
Management Commentary
Cemtrex Chairman and CEO, Saagar Govil, commented on the results: “In the third quarter we continued to see momentum in our segments, sustaining revenue year over year at $14.7 million. Significant demand for AIS products and services drove a 49% increase in revenue to $8.5 million, offset by decreases in Vicon revenue due to the delay of multiple projects and a weaker industrywide demand for security solutions.
“Operating loss for the third quarter was $3.2 million, compared to operating income of $0.1 million a year ago, mainly due to decreased gross profit in our Security segment and increased G&A expenses. The operating loss for the nine-month period was $5.0 million compared to $1.5 million a year ago, despite the higher sales. However, these results include approximately $2 million in one-time expenses related to the May 2024 equity financing, employee related one-time charges and legal expenses. Our goal of achieving a full year operating profit remains and we are working hard to drive revenue and maintain tight cost controls.
“In our Security segment, despite project delays, the team at Vicon continues to push the deployment of new technologies and products with investments into sales and marketing resources that we believe will drive sales over the next several quarters. We also were able to reduce our inventory by over $1 million this fiscal year as we strive to make our operations more efficient. We expect with the launch of the innovative new cloud security platform Anavio, along with new technologies and continued improvements to our core software platform Valerus, there is significant further opportunity to grow revenue and gross margin over the next several quarters.
“Our Industrial services segment delivered another strong quarter on orders from leading companies, building a pipeline of growth that we believe will produce a record year of revenue. We continue to believe with additional orders ahead, AIS has the potential to reach more than 30% annual revenue growth in FY’24, with further room for growth in FY 25.
“During the quarter we took the opportunity to improve our balance sheet with a $10 million upsized underwritten public offering, of which a portion of the proceeds were used to pay off some of our indebtedness. Looking ahead, we are now well positioned for additional growth and to reach our goal to achieve positive operating income in the future. The strengthened balance sheet also provides the ability to explore acquisition opportunities that can enhance our market reach and service capabilities, as we continue to seek long-term value for our shareholders,” concluded Govil.
Third Quarter FY 2024 Financial Results
Revenue for the three months ended June 30, 2024, and 2023 was $14.7 million and $14.7 million, respectively. The Security segment revenues for the three months ended June 30, 2024, decreased by 31% to $6.2 million. The Security segment decrease was due to the delay of multiple projects for the Security segment’s products and services and overall worsening economic conditions in the industry. The Industrial Services segment revenues for the third quarter increased by 49% to $8.5 million, mainly due to increased demand for the segment’s services as well as additional business from the Heisey acquisition completed during the fourth quarter of fiscal year 2023.
Gross Profit for the three months ended June 30, 2024, was $5.9 million, or 40% of revenues, as compared to gross profit of $6.5 million, or 44% of revenues, for the three months ended June 30, 2023.
Total operating expenses for three months ended June 30, 2024, were $9.1 million, compared to $6.4 million in the prior year’s quarter.
Operating loss for the third quarter of 2024 was $3.2 million as compared to an operating income of $0.1 million for the third quarter of 2023. The operating loss was primarily due to a decrease in gross profit in the Security segment and overall increased general and administration expenses.
Net loss for the quarter ended June 30, 2024 was $9.1 million, as compared to a net loss of $1.2 million in the prior year’s quarter.
Cash, cash equivalents and restricted cash totaled $7.6 million at June 30, 2024, as compared to $6.3 million at September 30, 2023.
Inventories decreased to $7.5 million at June 30, 2024, from $8.7 million at September 30, 2023.
Third Quarter FY 2024 Results Conference Call
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at http://www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.
$BLIS News: NAPC Defense, Inc. (OTCPK: BLIS) updates Progress with Saudi Arabia regarding Future Plans and CornerShot Demonstrations
LARGO, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that its representatives have returned from their meetings with interested parties in Europe and Saudi Arabia, concerning its CornerShot products, various munitions, and other military hardware.
The NAPC representatives made progress with their Saudi Arabian counterparts and the potential for proposed contracts remains promising. NAPC received a $253,000 Purchase Order to support technical activity and expertise for CornerShot, drones, and other munitions. This support requires sending in country personnel to assist the Saudi Ministry of Defense (“MOD”) with technical questions and training.
https://ml.globenewswire.com/Resource/Download/bfacedcc-0a5d-4443-9534-c3db982e152a/napc-saudi.jpeg
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
NAPC representatives are expected to return to Saudi Arabia by the end of August to support a seven-day demo event and to advance its existing large intended order for CornerShot. Due to unexpected active military activities on the Saudi Arabian border during NAPC’s recent trip, civilians in general, including the Company’s representatives, were restricted access to conduct the necessary CornerShot demonstrations with MOD leaders and soldiers.
John Spence, NAPC Defense’s CFO and weapons specialist, stated, “Our visit with leaders in Saudi Arabia advanced our relationship in so many positive ways. We appreciated the hospitality and eagerness to conduct business with our team, opening the door to many new potential contracts. We also fully expect NAPC Defense to finalize agreements for large orders of CornerShot following live demonstrations.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S. and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with U.S. State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfacedcc-0a5d-4443-9534-c3db982e152a
https://www.globenewswire.com/newsroom/ti?nf=OTIwMzgwNCM2NDIwOTEyIzIyNjE1MDY=
https://ml.globenewswire.com/media/NTVkMTJlYTctY2MxNS00NjJjLWE2OWMtY2MyZTk0Y2QyYzNjLTEyNzMwNTY=/tiny/Treasure-Shipwreck-Recovery-In.png
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Source: NAPC Defense, Inc.
© 2024 GlobeNewswire, Inc.
$BLIS News: NAPC Defense, Inc. (OTCPK: BLIS) updates Progress with Saudi Arabia regarding Future Plans and CornerShot Demonstrations
LARGO, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that its representatives have returned from their meetings with interested parties in Europe and Saudi Arabia, concerning its CornerShot products, various munitions, and other military hardware.
The NAPC representatives made progress with their Saudi Arabian counterparts and the potential for proposed contracts remains promising. NAPC received a $253,000 Purchase Order to support technical activity and expertise for CornerShot, drones, and other munitions. This support requires sending in country personnel to assist the Saudi Ministry of Defense (“MOD”) with technical questions and training.
https://ml.globenewswire.com/Resource/Download/bfacedcc-0a5d-4443-9534-c3db982e152a/napc-saudi.jpeg
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
NAPC representatives are expected to return to Saudi Arabia by the end of August to support a seven-day demo event and to advance its existing large intended order for CornerShot. Due to unexpected active military activities on the Saudi Arabian border during NAPC’s recent trip, civilians in general, including the Company’s representatives, were restricted access to conduct the necessary CornerShot demonstrations with MOD leaders and soldiers.
John Spence, NAPC Defense’s CFO and weapons specialist, stated, “Our visit with leaders in Saudi Arabia advanced our relationship in so many positive ways. We appreciated the hospitality and eagerness to conduct business with our team, opening the door to many new potential contracts. We also fully expect NAPC Defense to finalize agreements for large orders of CornerShot following live demonstrations.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S. and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with U.S. State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfacedcc-0a5d-4443-9534-c3db982e152a
https://www.globenewswire.com/newsroom/ti?nf=OTIwMzgwNCM2NDIwOTEyIzIyNjE1MDY=
https://ml.globenewswire.com/media/NTVkMTJlYTctY2MxNS00NjJjLWE2OWMtY2MyZTk0Y2QyYzNjLTEyNzMwNTY=/tiny/Treasure-Shipwreck-Recovery-In.png
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Source: NAPC Defense, Inc.
© 2024 GlobeNewswire, Inc.
$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content
First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content
JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.
The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.
Key Findings:
Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.
Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."
For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.
About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.
About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html
SOURCE Safety Shot
$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content
First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content
JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.
The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.
Key Findings:
Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.
Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."
For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.
About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.
About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html
SOURCE Safety Shot
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
Company is now funded for and focused on New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics is now complete, SEC filing of spinout this quarter
Key Milestones
Secured $10.8 - $16.3 million in convertible-debt funding from an institutional investor; funds targeted to support FDA New Drug Applications for NRX-100 (ketamine) and NRX-101. Replacement funding entails substantial reduction in interest rate, conversion discount, and other financial terms compared to prior debt
Retirement of Streeterville debt and settlement of litigation at a substantial discount to litigation claims
NRX-100 NDA for suicidal depression based on data from four clinical trials in nearly 1000 participants demonstrating highly significant efficacy compared to placebo, active comparator, and electroshock therapy
Ketamine findings have just been confirmed in published 43,000 person cohort study1
Phase 2b/3 trial of NRX-101 in suicidal patients with bipolar depression demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025) and time to sustained remission from suicidality (P=.05). Presented at the annual meeting of the American Society of Clinical Psychopharmacology. Profile demonstrates possible best in class bipolar depression medication
Company plans to file a New Drug Application (NDA) for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101 in treatment of bipolar depression in people akathisia or suicidality, based on the Phase 2b/3 and STABIL-B data
Stability data continues to mature on the three manufacturing lots required for the NRX-100 (IV ketamine) NDA filing and the Company announced alignment with FDA on its Pediatric Study Plan for NRX-100, also a requirement for filing an NDA
HOPE Therapeutics, the Company's wholly owned subsidiary, is focused on developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders, and new investors. This effort will be funded apart from NRx.
Appointed Dr. Dennis McBride, a Neuroscience, Information Technology and Medical Technology Veteran, to its Board of Directors
Management to host a conference call August 14, 2024, at 4:30 PM ET
RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended June 30, 2024, and provided a business update.
"NRx has continued to execute on our plans to file two NDA's this year. As we near maturation of NRX-100 stability data, we also achieved an important milestone in aligning with FDA on our pediatric study plan. Together with strong clinical data from four clinical trials, we believe this application will be quite robust. Additionally, the important data generated from two trials conducted by NRx with NRX-101 in suicidal bipolar depression sets the stage for a second NDA for Accelerated Approval later this year. Finally, work continues to spin out Hope Therapeutics and distribute shares to NRx stockholders. We believe reaching these important milestones will generate significant value in the company and reward our shareholders," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "Facilitated by funding to allow us to achieve these goals and while replacing the prior expensive and toxic debt on our balance sheet, we are in a position to deliver therapy that can meet considerable unmet medical need in millions of patients across the country. We are dedicated to bringing hope to life and I thank our team and shareholders for their ongoing hard work and support."
Second Quarter Clinical, Regulatory and Corporate Highlights
Funding for FDA filings of NRX-100 and NRX-101
The Company has executed a Convertible Debt instrument with Anson Funds of Toronto for $10.8 - $16.3 million in funding designed to retire existing debt and to support FDA New Drug filings of NRX-100 and NRX-101 in the fourth quarter of 2024. Terms have been disclosed in 8K filings but are at an interest rate and conversion rate substantially lower than current corporate indebtedness. The new funding has no provision for "extraordinary redemptions" triggered by appreciation in NRx share price.
Retirement of current debt and settlement of litigation
Concurrent with the Anson investment, the Company has settled its outstanding litigation with Streeterville Capital, LLC at a substantial discount to the amounts claimed in litigation.
Progress towards an NDA for NRX-100 (IV ketamine) in the treatment of suicidal depression
Intravenous ketamine has now become a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product. Intranasal Esketamine is approved by the FDA (SPRAVATO®) but has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression. Attempts to use intranasal racemic ketamine for suicidal depression have failed.
The Company has formed data-sharing partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality. The Company's role is to reformat these data into the required presentation required for review by the FDA.
In contrast to nasal ketamine, Intravenous racemic ketamine demonstrates dramatic and immediate reduction of suicidality in patients with both Major Depressive Disorder and Bipolar Depression. Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry Grunebaum, et.al.2. Abbar and colleagues similarly published 84% remission from suicidality on the Columbia Suicide Severity Rating Scale (C-SSRS) in patients treated with ketamine, vs. 28% in those treated with placebo (P<.0001). This trial was published in the British Medical Journal3. Data are expected to be transmitted to FDA by in 2024.
In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. Nine months of real-time stability is ongoing, the minimum stability time required for a New Drug Application. This presentation of ketamine does not contain the preservative included in multi-dose vials, (Benzanthonium Chloride), that is designed to preserve sterility in the vial when multiple doses are drawn for multiple patients. The Company is not aware of any data to support the safety of this preservative for repeated IV administration. Data were collected 20 years ago that demonstrated the toxic effect of this class of preservatives when applied repeatedly to the surface of the eye, which led to the current generation of preservative-free eye drops. NRX-100 will therefore be launched as a preservative-free presentation.
A long-term challenge with ketamine is that the current formulation (KETALAR®) is highly acidic. While it is suitable for intravenous use, it cannot be administered subcutaneously. In March 2024 the Company demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
Development of NRX-101 for Suicidal Treatment-Resistant Suicidal Bipolar Depression
The Company presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
Incorporation of HOPE Therapeutics
In February we first presented the contours of HOPE Therapeutics, a subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRx Pharmaceuticals, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. As currently designed, the HOPE consolidation is likely to be funded as a separate entity, through bond offerings and, thus, to be non-dilutive to NRx shareholders. Over the past quarter, HOPE leadership has identified the clinics that are most likely to participate in the first $100 million consolidation, has completed the audit required for a public listing of HOPE shares, and has identified appropriate underwriters for a future bond offering.
With Hope ownership as an asset of NRx, this will further strengthen the NRx balance sheet and aims to further enhance NRx shareholder value.
NRX-101 for Treatment of Chronic Pain:
In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.)6. There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.)7. Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
A key challenge in the treatment of cUTI is the tendency of advanced antibiotics to cause C. difficile infection, which is fatal in 10% of those who contract it over the age of 65 and results in prolonged hospitalization in many more. The Company recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
In The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Financial Results for the Quarter and Year to Date 2024
For the three months ended June 30, 2024, we at NRx Pharmaceuticals reduced our net loss from $8.7 million in the second quarter of 2023 to $7.9 million in 2024, representing nearly a 10% improvement year over year. For that same period, we reduced research and development expenses from $3.9 million in 2023 to $2.8 million in 2024. The $1.1 million decrease is related primarily to a decrease of $2.4 million in clinical trial and development expenses, offset by an increase of $1.3m related to the Alvogen warrants. Also in that 3 month period we recorded an increase in general and administrative expenses, from $4.1 million in 2023 to $4.2 million in 2024. The increase of $0.1 million is related primarily to an increase in consultants and legal fees partially offset by lower insurance expenses.
For the six months ended June 30, 2024, NRx Pharmaceuticals reduced its net loss to $14.4 million compared to $19.8 million in the prior year. These efficiencies represent an improvement in net loss of $5.4 million year over and a $1.32, or 47%, improvement in net loss per share year over year. Over that six-month period we recorded $4.6 million of research and development expenses compared to $7.5 million for the same period in 2023 representing a 39% decrease year over year. The decrease of $2.9 million is related primarily to a decrease of $4.1 million in clinical trial and development expenses, $0.3 million related to fees paid to regulatory and process development consultants while offset by $1.3 million related to the Alvogen warrants and $0.4 million related to fees paid to regulatory and development consultants. Also in that six-month period, we decreased G&A by $1.4 million, from $9.9 million in 2023 to $8.5 million in 2024, nearly a 15% decrease year over year.
As of June 30, 2024, we had $1.9 million in cash and cash equivalents. As previously stated, we recently announced we secured up to $16.3 Million Senior Secured Debt Financing from Anson Funds. This financing is expected to support 2024 filing of New Drug Applications for NRX-100 (ketamine) and NRX-101 and to support launch of HOPE Therapeutics as well as retire historical debt with more favorable terms, and a lower annual interest rate.
NRx continues to implement operational efficiencies to extend cash runway and maintain focus on our path to generating revenue and value for our shareholders.
Please see detailed financials on our Form 10-Q, filed with the SEC and available on our website.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 4:30 p.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Pan, Y., Gorenflo, M.P., Davis, P.B. et al. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study. Transl Psychiatry 14, 327 (2024). https://doi.org/10.1038/s41398-024-03033-4
2 Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
3 Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
4 Nierenberg, et. al., A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/ lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior. Am Soc Clin Psych Annual Meeting 2024.
5 Nierenberg et al. International Journal of Bipolar Disorders (2023) 11:28 https://doi.org/10.1186/s40345-023-00
6 https://www.cdc.gov/sepsis/what-is-sepsis.html
7 Open Forum Infectious Diseases, Volume 9, Issue 7, July 2022, ofac315, https://doi.org/10.1093/ofid/ofac315
https://c212.net/c/img/favicon.png?sn=CL84005&sd=2024-08-14 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-second-quarter-and-year-to-date-2024-financial-results-and-provides-business-update-302222664.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
Company is now funded for and focused on New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics is now complete, SEC filing of spinout this quarter
Key Milestones
Secured $10.8 - $16.3 million in convertible-debt funding from an institutional investor; funds targeted to support FDA New Drug Applications for NRX-100 (ketamine) and NRX-101. Replacement funding entails substantial reduction in interest rate, conversion discount, and other financial terms compared to prior debt
Retirement of Streeterville debt and settlement of litigation at a substantial discount to litigation claims
NRX-100 NDA for suicidal depression based on data from four clinical trials in nearly 1000 participants demonstrating highly significant efficacy compared to placebo, active comparator, and electroshock therapy
Ketamine findings have just been confirmed in published 43,000 person cohort study1
Phase 2b/3 trial of NRX-101 in suicidal patients with bipolar depression demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025) and time to sustained remission from suicidality (P=.05). Presented at the annual meeting of the American Society of Clinical Psychopharmacology. Profile demonstrates possible best in class bipolar depression medication
Company plans to file a New Drug Application (NDA) for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101 in treatment of bipolar depression in people akathisia or suicidality, based on the Phase 2b/3 and STABIL-B data
Stability data continues to mature on the three manufacturing lots required for the NRX-100 (IV ketamine) NDA filing and the Company announced alignment with FDA on its Pediatric Study Plan for NRX-100, also a requirement for filing an NDA
HOPE Therapeutics, the Company's wholly owned subsidiary, is focused on developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders, and new investors. This effort will be funded apart from NRx.
Appointed Dr. Dennis McBride, a Neuroscience, Information Technology and Medical Technology Veteran, to its Board of Directors
Management to host a conference call August 14, 2024, at 4:30 PM ET
RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended June 30, 2024, and provided a business update.
"NRx has continued to execute on our plans to file two NDA's this year. As we near maturation of NRX-100 stability data, we also achieved an important milestone in aligning with FDA on our pediatric study plan. Together with strong clinical data from four clinical trials, we believe this application will be quite robust. Additionally, the important data generated from two trials conducted by NRx with NRX-101 in suicidal bipolar depression sets the stage for a second NDA for Accelerated Approval later this year. Finally, work continues to spin out Hope Therapeutics and distribute shares to NRx stockholders. We believe reaching these important milestones will generate significant value in the company and reward our shareholders," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "Facilitated by funding to allow us to achieve these goals and while replacing the prior expensive and toxic debt on our balance sheet, we are in a position to deliver therapy that can meet considerable unmet medical need in millions of patients across the country. We are dedicated to bringing hope to life and I thank our team and shareholders for their ongoing hard work and support."
Second Quarter Clinical, Regulatory and Corporate Highlights
Funding for FDA filings of NRX-100 and NRX-101
The Company has executed a Convertible Debt instrument with Anson Funds of Toronto for $10.8 - $16.3 million in funding designed to retire existing debt and to support FDA New Drug filings of NRX-100 and NRX-101 in the fourth quarter of 2024. Terms have been disclosed in 8K filings but are at an interest rate and conversion rate substantially lower than current corporate indebtedness. The new funding has no provision for "extraordinary redemptions" triggered by appreciation in NRx share price.
Retirement of current debt and settlement of litigation
Concurrent with the Anson investment, the Company has settled its outstanding litigation with Streeterville Capital, LLC at a substantial discount to the amounts claimed in litigation.
Progress towards an NDA for NRX-100 (IV ketamine) in the treatment of suicidal depression
Intravenous ketamine has now become a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product. Intranasal Esketamine is approved by the FDA (SPRAVATO®) but has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression. Attempts to use intranasal racemic ketamine for suicidal depression have failed.
The Company has formed data-sharing partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality. The Company's role is to reformat these data into the required presentation required for review by the FDA.
In contrast to nasal ketamine, Intravenous racemic ketamine demonstrates dramatic and immediate reduction of suicidality in patients with both Major Depressive Disorder and Bipolar Depression. Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry Grunebaum, et.al.2. Abbar and colleagues similarly published 84% remission from suicidality on the Columbia Suicide Severity Rating Scale (C-SSRS) in patients treated with ketamine, vs. 28% in those treated with placebo (P<.0001). This trial was published in the British Medical Journal3. Data are expected to be transmitted to FDA by in 2024.
In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. Nine months of real-time stability is ongoing, the minimum stability time required for a New Drug Application. This presentation of ketamine does not contain the preservative included in multi-dose vials, (Benzanthonium Chloride), that is designed to preserve sterility in the vial when multiple doses are drawn for multiple patients. The Company is not aware of any data to support the safety of this preservative for repeated IV administration. Data were collected 20 years ago that demonstrated the toxic effect of this class of preservatives when applied repeatedly to the surface of the eye, which led to the current generation of preservative-free eye drops. NRX-100 will therefore be launched as a preservative-free presentation.
A long-term challenge with ketamine is that the current formulation (KETALAR®) is highly acidic. While it is suitable for intravenous use, it cannot be administered subcutaneously. In March 2024 the Company demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
Development of NRX-101 for Suicidal Treatment-Resistant Suicidal Bipolar Depression
The Company presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
Incorporation of HOPE Therapeutics
In February we first presented the contours of HOPE Therapeutics, a subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRx Pharmaceuticals, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. As currently designed, the HOPE consolidation is likely to be funded as a separate entity, through bond offerings and, thus, to be non-dilutive to NRx shareholders. Over the past quarter, HOPE leadership has identified the clinics that are most likely to participate in the first $100 million consolidation, has completed the audit required for a public listing of HOPE shares, and has identified appropriate underwriters for a future bond offering.
With Hope ownership as an asset of NRx, this will further strengthen the NRx balance sheet and aims to further enhance NRx shareholder value.
NRX-101 for Treatment of Chronic Pain:
In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.)6. There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.)7. Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
A key challenge in the treatment of cUTI is the tendency of advanced antibiotics to cause C. difficile infection, which is fatal in 10% of those who contract it over the age of 65 and results in prolonged hospitalization in many more. The Company recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
In The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Financial Results for the Quarter and Year to Date 2024
For the three months ended June 30, 2024, we at NRx Pharmaceuticals reduced our net loss from $8.7 million in the second quarter of 2023 to $7.9 million in 2024, representing nearly a 10% improvement year over year. For that same period, we reduced research and development expenses from $3.9 million in 2023 to $2.8 million in 2024. The $1.1 million decrease is related primarily to a decrease of $2.4 million in clinical trial and development expenses, offset by an increase of $1.3m related to the Alvogen warrants. Also in that 3 month period we recorded an increase in general and administrative expenses, from $4.1 million in 2023 to $4.2 million in 2024. The increase of $0.1 million is related primarily to an increase in consultants and legal fees partially offset by lower insurance expenses.
For the six months ended June 30, 2024, NRx Pharmaceuticals reduced its net loss to $14.4 million compared to $19.8 million in the prior year. These efficiencies represent an improvement in net loss of $5.4 million year over and a $1.32, or 47%, improvement in net loss per share year over year. Over that six-month period we recorded $4.6 million of research and development expenses compared to $7.5 million for the same period in 2023 representing a 39% decrease year over year. The decrease of $2.9 million is related primarily to a decrease of $4.1 million in clinical trial and development expenses, $0.3 million related to fees paid to regulatory and process development consultants while offset by $1.3 million related to the Alvogen warrants and $0.4 million related to fees paid to regulatory and development consultants. Also in that six-month period, we decreased G&A by $1.4 million, from $9.9 million in 2023 to $8.5 million in 2024, nearly a 15% decrease year over year.
As of June 30, 2024, we had $1.9 million in cash and cash equivalents. As previously stated, we recently announced we secured up to $16.3 Million Senior Secured Debt Financing from Anson Funds. This financing is expected to support 2024 filing of New Drug Applications for NRX-100 (ketamine) and NRX-101 and to support launch of HOPE Therapeutics as well as retire historical debt with more favorable terms, and a lower annual interest rate.
NRx continues to implement operational efficiencies to extend cash runway and maintain focus on our path to generating revenue and value for our shareholders.
Please see detailed financials on our Form 10-Q, filed with the SEC and available on our website.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 4:30 p.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Pan, Y., Gorenflo, M.P., Davis, P.B. et al. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study. Transl Psychiatry 14, 327 (2024). https://doi.org/10.1038/s41398-024-03033-4
2 Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
3 Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
4 Nierenberg, et. al., A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/ lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior. Am Soc Clin Psych Annual Meeting 2024.
5 Nierenberg et al. International Journal of Bipolar Disorders (2023) 11:28 https://doi.org/10.1186/s40345-023-00
6 https://www.cdc.gov/sepsis/what-is-sepsis.html
7 Open Forum Infectious Diseases, Volume 9, Issue 7, July 2022, ofac315, https://doi.org/10.1093/ofid/ofac315
https://c212.net/c/img/favicon.png?sn=CL84005&sd=2024-08-14 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-second-quarter-and-year-to-date-2024-financial-results-and-provides-business-update-302222664.html
SOURCE NRx Pharmaceuticals, Inc.
$IDVV News: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
$IDVV News: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
$CETX News: Cemtrex Reports Third Quarter 2024 Financial Results
Q3’24 Industrial Services Segment Revenue Increased 49% to $8.5M
News Link:
https://finance.yahoo.com/news/cemtrex-reports-third-quarter-2024-201000128.html
Hauppauge, NY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its unaudited financial and operational results for the fiscal third quarter ended June 30, 2024.
Key Third Quarter FY 2024 and Subsequent Highlights
Revenue for Q3’24 was flat at $14.7 million, compared to revenue of $14.7 million for Q3’23. Security segment revenues decreased 31% to $6.2 million in Q3’24 due primarily to the delay of multiple projects for the segment’s products and services.Industrial Services segment revenues for Q3’24 increased 49% to $8.5 million, on increased demand and additional revenue from the Heisey Mechanical acquisition completed in Q4’23.
Revenue for the nine months ended June 30, 2024 increased 14% to $48.7 million, compared to revenue in the prior year period of $42.8 million. Security segment revenues for the nine months ended June 30, 2024, decreased 10% to $23.4 million compared to $25.9 million for the nine months ended June 30, 2023.Industrial Services segment revenues for the nine months ended June 30, 2024, increased 50% to $25.3 million compared to $16.8 million for the nine months ended June 30, 2023.
Closed $10 million upsized underwritten public offering to conduct operations, increase marketing efforts, invest in existing business initiatives and products, and for the partial repayment of indebtedness.
Cash, cash equivalents and restricted cash as of June 30, 2024 was $7.6 million, compared to $6.3 million as of September 30, 2023.
Management Commentary
Cemtrex Chairman and CEO, Saagar Govil, commented on the results: “In the third quarter we continued to see momentum in our segments, sustaining revenue year over year at $14.7 million. Significant demand for AIS products and services drove a 49% increase in revenue to $8.5 million, offset by decreases in Vicon revenue due to the delay of multiple projects and a weaker industrywide demand for security solutions.
“Operating loss for the third quarter was $3.2 million, compared to operating income of $0.1 million a year ago, mainly due to decreased gross profit in our Security segment and increased G&A expenses. The operating loss for the nine-month period was $5.0 million compared to $1.5 million a year ago, despite the higher sales. However, these results include approximately $2 million in one-time expenses related to the May 2024 equity financing, employee related one-time charges and legal expenses. Our goal of achieving a full year operating profit remains and we are working hard to drive revenue and maintain tight cost controls.
“In our Security segment, despite project delays, the team at Vicon continues to push the deployment of new technologies and products with investments into sales and marketing resources that we believe will drive sales over the next several quarters. We also were able to reduce our inventory by over $1 million this fiscal year as we strive to make our operations more efficient. We expect with the launch of the innovative new cloud security platform Anavio, along with new technologies and continued improvements to our core software platform Valerus, there is significant further opportunity to grow revenue and gross margin over the next several quarters.
“Our Industrial services segment delivered another strong quarter on orders from leading companies, building a pipeline of growth that we believe will produce a record year of revenue. We continue to believe with additional orders ahead, AIS has the potential to reach more than 30% annual revenue growth in FY’24, with further room for growth in FY 25.
“During the quarter we took the opportunity to improve our balance sheet with a $10 million upsized underwritten public offering, of which a portion of the proceeds were used to pay off some of our indebtedness. Looking ahead, we are now well positioned for additional growth and to reach our goal to achieve positive operating income in the future. The strengthened balance sheet also provides the ability to explore acquisition opportunities that can enhance our market reach and service capabilities, as we continue to seek long-term value for our shareholders,” concluded Govil.
Third Quarter FY 2024 Financial Results
Revenue for the three months ended June 30, 2024, and 2023 was $14.7 million and $14.7 million, respectively. The Security segment revenues for the three months ended June 30, 2024, decreased by 31% to $6.2 million. The Security segment decrease was due to the delay of multiple projects for the Security segment’s products and services and overall worsening economic conditions in the industry. The Industrial Services segment revenues for the third quarter increased by 49% to $8.5 million, mainly due to increased demand for the segment’s services as well as additional business from the Heisey acquisition completed during the fourth quarter of fiscal year 2023.
Gross Profit for the three months ended June 30, 2024, was $5.9 million, or 40% of revenues, as compared to gross profit of $6.5 million, or 44% of revenues, for the three months ended June 30, 2023.
Total operating expenses for three months ended June 30, 2024, were $9.1 million, compared to $6.4 million in the prior year’s quarter.
Operating loss for the third quarter of 2024 was $3.2 million as compared to an operating income of $0.1 million for the third quarter of 2023. The operating loss was primarily due to a decrease in gross profit in the Security segment and overall increased general and administration expenses.
Net loss for the quarter ended June 30, 2024 was $9.1 million, as compared to a net loss of $1.2 million in the prior year’s quarter.
Cash, cash equivalents and restricted cash totaled $7.6 million at June 30, 2024, as compared to $6.3 million at September 30, 2023.
Inventories decreased to $7.5 million at June 30, 2024, from $8.7 million at September 30, 2023.
Third Quarter FY 2024 Results Conference Call
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at http://www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
Company is now funded for and focused on New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics is now complete, SEC filing of spinout this quarter
Key Milestones
Secured $10.8 - $16.3 million in convertible-debt funding from an institutional investor; funds targeted to support FDA New Drug Applications for NRX-100 (ketamine) and NRX-101. Replacement funding entails substantial reduction in interest rate, conversion discount, and other financial terms compared to prior debt
Retirement of Streeterville debt and settlement of litigation at a substantial discount to litigation claims
NRX-100 NDA for suicidal depression based on data from four clinical trials in nearly 1000 participants demonstrating highly significant efficacy compared to placebo, active comparator, and electroshock therapy
Ketamine findings have just been confirmed in published 43,000 person cohort study1
Phase 2b/3 trial of NRX-101 in suicidal patients with bipolar depression demonstrated depression efficacy comparable to standard of care and significant reduction of akathisia (P=0.025) and time to sustained remission from suicidality (P=.05). Presented at the annual meeting of the American Society of Clinical Psychopharmacology. Profile demonstrates possible best in class bipolar depression medication
Company plans to file a New Drug Application (NDA) for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101 in treatment of bipolar depression in people akathisia or suicidality, based on the Phase 2b/3 and STABIL-B data
Stability data continues to mature on the three manufacturing lots required for the NRX-100 (IV ketamine) NDA filing and the Company announced alignment with FDA on its Pediatric Study Plan for NRX-100, also a requirement for filing an NDA
HOPE Therapeutics, the Company's wholly owned subsidiary, is focused on developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders. HOPE is planned to be spun out as a separate company to be owned by NRx, current NRx shareholders, and new investors. This effort will be funded apart from NRx.
Appointed Dr. Dennis McBride, a Neuroscience, Information Technology and Medical Technology Veteran, to its Board of Directors
Management to host a conference call August 14, 2024, at 4:30 PM ET
RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended June 30, 2024, and provided a business update.
"NRx has continued to execute on our plans to file two NDA's this year. As we near maturation of NRX-100 stability data, we also achieved an important milestone in aligning with FDA on our pediatric study plan. Together with strong clinical data from four clinical trials, we believe this application will be quite robust. Additionally, the important data generated from two trials conducted by NRx with NRX-101 in suicidal bipolar depression sets the stage for a second NDA for Accelerated Approval later this year. Finally, work continues to spin out Hope Therapeutics and distribute shares to NRx stockholders. We believe reaching these important milestones will generate significant value in the company and reward our shareholders," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "Facilitated by funding to allow us to achieve these goals and while replacing the prior expensive and toxic debt on our balance sheet, we are in a position to deliver therapy that can meet considerable unmet medical need in millions of patients across the country. We are dedicated to bringing hope to life and I thank our team and shareholders for their ongoing hard work and support."
Second Quarter Clinical, Regulatory and Corporate Highlights
Funding for FDA filings of NRX-100 and NRX-101
The Company has executed a Convertible Debt instrument with Anson Funds of Toronto for $10.8 - $16.3 million in funding designed to retire existing debt and to support FDA New Drug filings of NRX-100 and NRX-101 in the fourth quarter of 2024. Terms have been disclosed in 8K filings but are at an interest rate and conversion rate substantially lower than current corporate indebtedness. The new funding has no provision for "extraordinary redemptions" triggered by appreciation in NRx share price.
Retirement of current debt and settlement of litigation
Concurrent with the Anson investment, the Company has settled its outstanding litigation with Streeterville Capital, LLC at a substantial discount to the amounts claimed in litigation.
Progress towards an NDA for NRX-100 (IV ketamine) in the treatment of suicidal depression
Intravenous ketamine has now become a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product. Intranasal Esketamine is approved by the FDA (SPRAVATO®) but has not demonstrated a benefit on suicidality and is not approved for use in patients with bipolar depression. Attempts to use intranasal racemic ketamine for suicidal depression have failed.
The Company has formed data-sharing partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality. The Company's role is to reformat these data into the required presentation required for review by the FDA.
In contrast to nasal ketamine, Intravenous racemic ketamine demonstrates dramatic and immediate reduction of suicidality in patients with both Major Depressive Disorder and Bipolar Depression. Grunebaum and colleagues demonstrated a rapid and statistically significant reduction in Suicidal Ideation (SSI) at day 1 (p=0.0003) and in depression (P=0.0234), as measured by the Profile of Mood States (POMS) among patients randomized to IV Ketamine compared to those randomized to midazolam. This trial was published in the American Journal of Psychiatry Grunebaum, et.al.2. Abbar and colleagues similarly published 84% remission from suicidality on the Columbia Suicide Severity Rating Scale (C-SSRS) in patients treated with ketamine, vs. 28% in those treated with placebo (P<.0001). This trial was published in the British Medical Journal3. Data are expected to be transmitted to FDA by in 2024.
In November 2023, the Company initiated manufacture of ketamine together with Nephron Pharmaceuticals, Inc. (West Columbia, SC) to develop a single patient presentation of ketamine. Nine months of real-time stability is ongoing, the minimum stability time required for a New Drug Application. This presentation of ketamine does not contain the preservative included in multi-dose vials, (Benzanthonium Chloride), that is designed to preserve sterility in the vial when multiple doses are drawn for multiple patients. The Company is not aware of any data to support the safety of this preservative for repeated IV administration. Data were collected 20 years ago that demonstrated the toxic effect of this class of preservatives when applied repeatedly to the surface of the eye, which led to the current generation of preservative-free eye drops. NRX-100 will therefore be launched as a preservative-free presentation.
A long-term challenge with ketamine is that the current formulation (KETALAR®) is highly acidic. While it is suitable for intravenous use, it cannot be administered subcutaneously. In March 2024 the Company demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
Development of NRX-101 for Suicidal Treatment-Resistant Suicidal Bipolar Depression
The Company presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
Incorporation of HOPE Therapeutics
In February we first presented the contours of HOPE Therapeutics, a subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRx Pharmaceuticals, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. As currently designed, the HOPE consolidation is likely to be funded as a separate entity, through bond offerings and, thus, to be non-dilutive to NRx shareholders. Over the past quarter, HOPE leadership has identified the clinics that are most likely to participate in the first $100 million consolidation, has completed the audit required for a public listing of HOPE shares, and has identified appropriate underwriters for a future bond offering.
With Hope ownership as an asset of NRx, this will further strengthen the NRx balance sheet and aims to further enhance NRx shareholder value.
NRX-101 for Treatment of Chronic Pain:
In 2023, the Company licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD (NCT 03535688) in which patients with chronic pain were randomly assigned to DCS 400mg/day vs. placebo. Should these results support efficacy of DCS in the treatment of chronic low back pain, they are expected to provide a Breakthrough Therapy path towards treatment of chronic pain with DCS and DCS-containing medicines.
Treatment of Urinary Tract Infection (UTI) and Urosepsis:
Although treatment of UTI is quite different from use of NRX-101 to treat Central Nervous System disorders, D-cycloserine was originally developed as an antibiotic because of its role in disrupting the cell wall of certain pathogens. During Q3 2023, NRx tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRx was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections and urosepsis (i.e., sepsis originating in the urinary tract) has resulted in a marked increase in cUTI, hospitalization, and death from urosepsis. The US Center for Disease Control and Prevention reports that more than 1.7 million Americans contract sepsis each year, of whom at least 350,000 die during their hospitalization or are discharged to hospice (CDC Sepsis Ref.)6. There are approximately 3 million patients per year who contract cUTI in the US annually (Lodise, et. al.)7. Additionally, should NRX-101 succeed in clinical trials, the Company will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
A key challenge in the treatment of cUTI is the tendency of advanced antibiotics to cause C. difficile infection, which is fatal in 10% of those who contract it over the age of 65 and results in prolonged hospitalization in many more. The Company recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
In The Company does not anticipate funding this initiative with core NRx assets and is exploring structures for partnership opportunities. Should the Company or its partners succeed in serving 10% of the cUTI market, the Company believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Financial Results for the Quarter and Year to Date 2024
For the three months ended June 30, 2024, we at NRx Pharmaceuticals reduced our net loss from $8.7 million in the second quarter of 2023 to $7.9 million in 2024, representing nearly a 10% improvement year over year. For that same period, we reduced research and development expenses from $3.9 million in 2023 to $2.8 million in 2024. The $1.1 million decrease is related primarily to a decrease of $2.4 million in clinical trial and development expenses, offset by an increase of $1.3m related to the Alvogen warrants. Also in that 3 month period we recorded an increase in general and administrative expenses, from $4.1 million in 2023 to $4.2 million in 2024. The increase of $0.1 million is related primarily to an increase in consultants and legal fees partially offset by lower insurance expenses.
For the six months ended June 30, 2024, NRx Pharmaceuticals reduced its net loss to $14.4 million compared to $19.8 million in the prior year. These efficiencies represent an improvement in net loss of $5.4 million year over and a $1.32, or 47%, improvement in net loss per share year over year. Over that six-month period we recorded $4.6 million of research and development expenses compared to $7.5 million for the same period in 2023 representing a 39% decrease year over year. The decrease of $2.9 million is related primarily to a decrease of $4.1 million in clinical trial and development expenses, $0.3 million related to fees paid to regulatory and process development consultants while offset by $1.3 million related to the Alvogen warrants and $0.4 million related to fees paid to regulatory and development consultants. Also in that six-month period, we decreased G&A by $1.4 million, from $9.9 million in 2023 to $8.5 million in 2024, nearly a 15% decrease year over year.
As of June 30, 2024, we had $1.9 million in cash and cash equivalents. As previously stated, we recently announced we secured up to $16.3 Million Senior Secured Debt Financing from Anson Funds. This financing is expected to support 2024 filing of New Drug Applications for NRX-100 (ketamine) and NRX-101 and to support launch of HOPE Therapeutics as well as retire historical debt with more favorable terms, and a lower annual interest rate.
NRx continues to implement operational efficiencies to extend cash runway and maintain focus on our path to generating revenue and value for our shareholders.
Please see detailed financials on our Form 10-Q, filed with the SEC and available on our website.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 4:30 p.m. ET today, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
1 Pan, Y., Gorenflo, M.P., Davis, P.B. et al. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study. Transl Psychiatry 14, 327 (2024). https://doi.org/10.1038/s41398-024-03033-4
2 Grunebaum, et. al., Ketamine for Rapid Reduction of Suicidal Thoughts. Am J Psychiatry. 2018 Apr 1: 175(4): 327-335
3 Abbar, et. al. Ketamine for Acute Treatment of Severe Suicidal Ideation, BMJ 2022; 376
4 Nierenberg, et. al., A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/ lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior. Am Soc Clin Psych Annual Meeting 2024.
5 Nierenberg et al. International Journal of Bipolar Disorders (2023) 11:28 https://doi.org/10.1186/s40345-023-00
6 https://www.cdc.gov/sepsis/what-is-sepsis.html
7 Open Forum Infectious Diseases, Volume 9, Issue 7, July 2022, ofac315, https://doi.org/10.1093/ofid/ofac315
https://c212.net/c/img/favicon.png?sn=CL84005&sd=2024-08-14 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-second-quarter-and-year-to-date-2024-financial-results-and-provides-business-update-302222664.html
SOURCE NRx Pharmaceuticals, Inc.
$ACGX News: Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024
CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- via IBN --Alliance Creative Group, Inc., (http://www.ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Quarter Ending June 30, 2024.
Revenues for the Quarter ending June 30, 2024 ("Q2 2024") were $159,617 Gross Profits for the Quarter ending June 30, 2024 ("Q2 2024") were $159,617 Net Income for the Quarter ending June 30, 2024 ("Q2 2024") were $78,843.
The total assets on the Balance Sheet for the Alliance Creative Group as of 6/30/24 were $4,601,150.
The total outstanding common shares as of June 30, 2024 were 4,454,211 with 2,799,023 of those shares in the float - Same as the end of the last quarter.
The Company ended the quarter with $142,061 Cash on hand.
The property located at 1324 W. Devon Ave, Chicago, IL. 60660 is still listed for sale. There have not been any full listing price offers yet.
The full financial statement, balance sheet, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on www.ACGX,us in the investor relations section.
Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "The shares we own in www.PeopleVine.com have continued to be our strongest investment and asset. The conversations with some of the experienced and credible growth equity firms have progressed to the more enhanced due diligence stages. The Company has not made any final decisions but the interest level and the opportunities are very positive. The potential of partnering up with any of these firms would help accelerate PeopleVine's growth and increase their value while providing additional capital and quality resources.
The property that is located at 1324 W. Devon is still generating positive cash flow and is listed for sale. We have not received any full offers yet so we will continue those conversations to determine if it is worth selling for less or holding on a little longer while the property continues to improve in our opinion.
We are still in search of another strategic investment, acquisition, or partnership to continue to grow our positive cashflow and position ourselves for potentially larger opportunities. We will continue to update the public as things progress and will share more details as they become available."
About Alliance Creative Group, Inc.
Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit http://www.AllianceCreativeGroup.com or www.ACGX.us.
About PeopleVine
PeopleVine is a Software as a Service (SaaS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.
For more information http://www.PeopleVine.com
This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Relations and Media Contact
1-312-498-9769
info@ACGemail.com
$ACGX News: Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024
CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- via IBN --Alliance Creative Group, Inc., (http://www.ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Quarter Ending June 30, 2024.
Revenues for the Quarter ending June 30, 2024 ("Q2 2024") were $159,617 Gross Profits for the Quarter ending June 30, 2024 ("Q2 2024") were $159,617 Net Income for the Quarter ending June 30, 2024 ("Q2 2024") were $78,843.
The total assets on the Balance Sheet for the Alliance Creative Group as of 6/30/24 were $4,601,150.
The total outstanding common shares as of June 30, 2024 were 4,454,211 with 2,799,023 of those shares in the float - Same as the end of the last quarter.
The Company ended the quarter with $142,061 Cash on hand.
The property located at 1324 W. Devon Ave, Chicago, IL. 60660 is still listed for sale. There have not been any full listing price offers yet.
The full financial statement, balance sheet, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on www.ACGX,us in the investor relations section.
Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "The shares we own in www.PeopleVine.com have continued to be our strongest investment and asset. The conversations with some of the experienced and credible growth equity firms have progressed to the more enhanced due diligence stages. The Company has not made any final decisions but the interest level and the opportunities are very positive. The potential of partnering up with any of these firms would help accelerate PeopleVine's growth and increase their value while providing additional capital and quality resources.
The property that is located at 1324 W. Devon is still generating positive cash flow and is listed for sale. We have not received any full offers yet so we will continue those conversations to determine if it is worth selling for less or holding on a little longer while the property continues to improve in our opinion.
We are still in search of another strategic investment, acquisition, or partnership to continue to grow our positive cashflow and position ourselves for potentially larger opportunities. We will continue to update the public as things progress and will share more details as they become available."
About Alliance Creative Group, Inc.
Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit http://www.AllianceCreativeGroup.com or www.ACGX.us.
About PeopleVine
PeopleVine is a Software as a Service (SaaS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.
For more information http://www.PeopleVine.com
This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Relations and Media Contact
1-312-498-9769
info@ACGemail.com
$IVDN has strongly rising sales, new customers, new distributors, patent protection, little debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.
All of this has come together as a result of IVDN management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news below.
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html
Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html
Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html
The real facts are that IVDN has strongly rising sales, new customers, new distributors, patent protection, little debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.
All of this has come together as a result of IVDN management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news below which is fully accountable to the SEC for truthfulness and accuracy. Anything else posted by anonymous individuals on chat boards is accountable to no one and therefore has no credibility.
Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html
Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html
Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html
$CETX: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$CETX: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
RADNOR, Pa., Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter and year to date 2024 financial results after the market closes on Wednesday, August 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events . Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
https://c212.net/c/img/favicon.png?sn=CL82891&sd=2024-08-13 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-and-year-to-date-2024-financial-results-on-august-14-2024-302221376.html
SOURCE NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
RADNOR, Pa., Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter and year to date 2024 financial results after the market closes on Wednesday, August 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events . Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
https://c212.net/c/img/favicon.png?sn=CL82891&sd=2024-08-13 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-and-year-to-date-2024-financial-results-on-august-14-2024-302221376.html
SOURCE NRx Pharmaceuticals, Inc.
$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content
First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content
JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.
The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.
Key Findings:
Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.
Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."
For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.
About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.
About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html
SOURCE Safety Shot
$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content
First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content
JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.
The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.
Key Findings:
Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.
Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."
For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.
About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.
About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html
SOURCE Safety Shot
$ASTI News: Ascent Solar Technologies Details Financial and Industry Status After Reverse Stock Split
THORNTON, Colo., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today commented on its positioning withing the solar industry after its previously-announced reverse stock split, which takes effect before market open on August 15, 2024.
“By effecting the reverse stock split, we believe we have better positioned the company to succeed moving forward both in the near and long term. We have amassed enough liquidity to continue operations well into the first quarter of 2025, an important factor as we continue to pursue strategic partnerships and customer engagements within key industry verticals including space and aerospace,” said Paul Warley, CEO of Ascent Solar Technologies.
“As interest in solar technologies continue to grow throughout the space and aerospace industries, we believe Ascent’s thin-film solar PV technologies present a highly viable product offering that is ready for efficient application across multiple high-growth verticals. We have continued to expand our new business pipeline, while also achieving dramatic advancements in in our technology over the last year – both of which we see as positives for potential customers, as well as our current and prospective investors.”
About Ascent Solar Technologies, Inc.
Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com
Forward-Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" including statements about the financing transaction, our business strategy, and the potential uses of the proceeds from the transaction. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. We have based these forward-looking statements on our current assumptions, expectations, and projections about future events. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “will,” "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. No information in this press release should be construed as any indication whatsoever of our future revenues, stock price, or results of operations. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's filings with the Securities and Exchange Commission including those discussed under the heading “Risk Factors” in our most recently filed reports on Forms 10-K and 10-Q.
Media Contact
Spencer Herrmann
FischTank PR
ascent@fischtankpr.com
$ASTI News: Ascent Solar Technologies Details Financial and Industry Status After Reverse Stock Split
THORNTON, Colo., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today commented on its positioning withing the solar industry after its previously-announced reverse stock split, which takes effect before market open on August 15, 2024.
“By effecting the reverse stock split, we believe we have better positioned the company to succeed moving forward both in the near and long term. We have amassed enough liquidity to continue operations well into the first quarter of 2025, an important factor as we continue to pursue strategic partnerships and customer engagements within key industry verticals including space and aerospace,” said Paul Warley, CEO of Ascent Solar Technologies.
“As interest in solar technologies continue to grow throughout the space and aerospace industries, we believe Ascent’s thin-film solar PV technologies present a highly viable product offering that is ready for efficient application across multiple high-growth verticals. We have continued to expand our new business pipeline, while also achieving dramatic advancements in in our technology over the last year – both of which we see as positives for potential customers, as well as our current and prospective investors.”
About Ascent Solar Technologies, Inc.
Backed by 40 years of R&D, 15 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in environments where mass, performance, reliability, and resilience matter. Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial/commercial construction as well as an extensive range of consumer goods, revolutionizing the use cases and environments for solar power. Ascent Solar’s research and development center and 5-MW nameplate production facility is in Thornton, Colorado. To learn more, visit https://www.ascentsolar.com
Forward-Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" including statements about the financing transaction, our business strategy, and the potential uses of the proceeds from the transaction. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. We have based these forward-looking statements on our current assumptions, expectations, and projections about future events. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “will,” "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. No information in this press release should be construed as any indication whatsoever of our future revenues, stock price, or results of operations. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's filings with the Securities and Exchange Commission including those discussed under the heading “Risk Factors” in our most recently filed reports on Forms 10-K and 10-Q.
Media Contact
Spencer Herrmann
FischTank PR
ascent@fischtankpr.com
$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content
First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content
JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.
The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.
"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.
Key Findings:
Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.
Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."
For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.
About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.
About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.
https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html
SOURCE Safety Shot
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds
This financing is expected to support 2024 filing of New Drug Applications forNRX-100 (ketamine) and NRX-101 and to support launch of HOPE Therapeutics
Streeterville Capital has agreed to a settlement of all claims to be paid from the proceeds of this financing
RADNOR, Pa., Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has obtained up to approximately $16 million in convertible debt financing (the "Financing") from an institutional investor. The Company intends to use the net proceeds from the Financing to support the 2024 New Drug Application filing its two lead products, NRX-100 and NRX-101 and to retire existing debt from Streeterville Capital. Concurrent with this financing, Streeterville has agreed to stay its arbitration and to release all claims upon receipt of the agreed settlement funds. The interest rate and other costs of capital are substantially lower than prior debt.
"We are thrilled to have attracted a forward-looking science-focused investor to our company. The proceeds from their investment will support our FDA filing of two lifesaving drugs that address critical unmet medical needs for patients with suicidal depression. In the process, we are retiring problematic debt from our balance sheet on favorable terms, and at a lower annual interest rate," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "We are pleased to welcome Anson Funds to NRx Pharmaceuticals and delighted that they have chosen to share our mission of bringing Hope to Life."
"NRx Pharmaceuticals has a promising pipeline with potential to transform the lives of patients and their loved ones. We are pleased to be working with the NRx Pharmaceuticals team to support these drugs in their registration and – hopefully – approval phase," said Amin Nathoo, Principal, Anson Funds.
The Notes have an interest rate of 6% per annum with a term of 15 months and will be convertible into shares of the Company's common stock. The investors will receive warrant coverage equivalent to 50% of their investment, exercisable into shares of the Company's common stock. The conversion price of the Notes and the exercise price of the Warrants will be each subject to customary adjustments and adjustments for certain corporate transactions, and the issuance of shares of Common Stock underlying the Notes and Warrants will be subject to stockholder approval as required by the listing rules of the Nasdaq Capital Market. The Company will file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission, which will describe the terms of the Notes and Warrants, and include copies of transaction documents relating to the Notes, the Warrants and the Financing.
EF Hutton LLC acted as the exclusive placement agent for the Financing.
The Notes and Warrants have not been registered under the Securities Act of 1933, as amended, and may not be resold in the United States except pursuant to an effective registration statement with the Securities and Exchange Commission or an exemption from registration under the Securities Act and any applicable state securities laws.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx Pharmaceuticals has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx Pharmaceuticals was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which involve substantial risks and uncertainties. Forward-looking statements are often identifiable by the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," "will," or "would," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for making each forward-looking statement contained in this press release, the Company cautions that these statements are based on a combination of facts and factors currently known by the Company and its expectations of the future, about which the Company cannot be certain. Forward-looking statements are subject to considerable risks and uncertainties, as well as other factors that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to whether or not the Company will be able to raise capital through the sale of its securities; the Company's ability to consummate the offering; the Company's ability to repay the Note; the Company being able to fulfill the conditions for a second closing and a third closing and receive the remainder of the financing amount; the Company being able to receive the consent of its stockholders to the Financing; market conditions; satisfaction of customary closing conditions related to future closings; the Company's ability to maintain adequate liquidity and financing sources; various risks related to the Company's business operations; and other risks and uncertainties, including those described within the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and other filings with the Securities and Exchange Commission.
Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL82597&sd=2024-08-13 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-up-to-16-million-senior-secured-debt-financing-from-anson-funds-302220794.html
SOURCE NRx Pharmaceuticals, Inc.
$CETX: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$CETX: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$BLIS News: NAPC Defense, Inc. (OTCPK: BLIS) updates Progress with Saudi Arabia regarding Future Plans and CornerShot Demonstrations
LARGO, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that its representatives have returned from their meetings with interested parties in Europe and Saudi Arabia, concerning its CornerShot products, various munitions, and other military hardware.
The NAPC representatives made progress with their Saudi Arabian counterparts and the potential for proposed contracts remains promising. NAPC received a $253,000 Purchase Order to support technical activity and expertise for CornerShot, drones, and other munitions. This support requires sending in country personnel to assist the Saudi Ministry of Defense (“MOD”) with technical questions and training.
https://ml.globenewswire.com/Resource/Download/bfacedcc-0a5d-4443-9534-c3db982e152a/napc-saudi.jpeg
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
NAPC representatives are expected to return to Saudi Arabia by the end of August to support a seven-day demo event and to advance its existing large intended order for CornerShot. Due to unexpected active military activities on the Saudi Arabian border during NAPC’s recent trip, civilians in general, including the Company’s representatives, were restricted access to conduct the necessary CornerShot demonstrations with MOD leaders and soldiers.
John Spence, NAPC Defense’s CFO and weapons specialist, stated, “Our visit with leaders in Saudi Arabia advanced our relationship in so many positive ways. We appreciated the hospitality and eagerness to conduct business with our team, opening the door to many new potential contracts. We also fully expect NAPC Defense to finalize agreements for large orders of CornerShot following live demonstrations.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S. and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with U.S. State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfacedcc-0a5d-4443-9534-c3db982e152a
https://www.globenewswire.com/newsroom/ti?nf=OTIwMzgwNCM2NDIwOTEyIzIyNjE1MDY=
https://ml.globenewswire.com/media/NTVkMTJlYTctY2MxNS00NjJjLWE2OWMtY2MyZTk0Y2QyYzNjLTEyNzMwNTY=/tiny/Treasure-Shipwreck-Recovery-In.png
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Source: NAPC Defense, Inc.
© 2024 GlobeNewswire, Inc.
$BLIS News: NAPC Defense, Inc. (OTCPK: BLIS) updates Progress with Saudi Arabia regarding Future Plans and CornerShot Demonstrations
LARGO, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc., (OTCPK: BLIS) (“NAPC” or “the Company”) announces that its representatives have returned from their meetings with interested parties in Europe and Saudi Arabia, concerning its CornerShot products, various munitions, and other military hardware.
The NAPC representatives made progress with their Saudi Arabian counterparts and the potential for proposed contracts remains promising. NAPC received a $253,000 Purchase Order to support technical activity and expertise for CornerShot, drones, and other munitions. This support requires sending in country personnel to assist the Saudi Ministry of Defense (“MOD”) with technical questions and training.
https://ml.globenewswire.com/Resource/Download/bfacedcc-0a5d-4443-9534-c3db982e152a/napc-saudi.jpeg
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
NAPC representatives are expected to return to Saudi Arabia by the end of August to support a seven-day demo event and to advance its existing large intended order for CornerShot. Due to unexpected active military activities on the Saudi Arabian border during NAPC’s recent trip, civilians in general, including the Company’s representatives, were restricted access to conduct the necessary CornerShot demonstrations with MOD leaders and soldiers.
John Spence, NAPC Defense’s CFO and weapons specialist, stated, “Our visit with leaders in Saudi Arabia advanced our relationship in so many positive ways. We appreciated the hospitality and eagerness to conduct business with our team, opening the door to many new potential contracts. We also fully expect NAPC Defense to finalize agreements for large orders of CornerShot following live demonstrations.”
About NAPC Defense, Inc.
NAPC Defense, Inc. https://www.napcdefense.com/ is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S. and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with U.S. State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.
These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO (754) 242-6272 Ext.713
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfacedcc-0a5d-4443-9534-c3db982e152a
https://www.globenewswire.com/newsroom/ti?nf=OTIwMzgwNCM2NDIwOTEyIzIyNjE1MDY=
https://ml.globenewswire.com/media/NTVkMTJlYTctY2MxNS00NjJjLWE2OWMtY2MyZTk0Y2QyYzNjLTEyNzMwNTY=/tiny/Treasure-Shipwreck-Recovery-In.png
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Pictured from left to right are John Spence, NAPC CFO, Stephen Gurba, NAPC President, Eng. Abdullah Mohamed Al Bassami, and Eng. Abdul Qader AI Bassami; in front of Saudi Prince’s Palace, during their recent meetings.
Source: NAPC Defense, Inc.
© 2024 GlobeNewswire, Inc.
$CETX: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$CETX: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$CYCA Reticulate Micro Launches $10M Reg A Capital Raise
Link: https://reticulate.io/reticulate-micro-launches-10m-reg-a-capital-raise/
Digital Offering Allows Defense Tech Provider to Democratize its Offering to Public Investors
PALM BAY, Fla. / August 1, 2024 / Reticulate Micro, Inc. (“Reticulate Micro,” “Reticulate” or the “Company”), a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, has launched its Regulation A stock offering to raise up to $10 million (the “Reg A Offering”) to support Reticulate’s product and market launch efforts as a leading provider of video compression and tactical and SATCOM management solutions. Its flagship product, VAST™, is designed to enable ultra-efficient streaming video and situational awareness in bandwidth-challenged environments.
Reticulate’s offering was qualified with the Securities and Exchange Commission (“SEC”) this week and allows anyone to now invest in the Company. The Reg A Offering has an offering price of $3.50 per unit. Each unit includes one share of the Company’s Class A Common Stock and one warrant to purchase one share of the Company’s Class A Common Stock at an exercise price of $5.50 per share. The minimum investment is $700 for 200 units and is open to all investors.
The lead selling agents for the transaction include Boustead Securities, LLC, a leading full-service investment banking firm and licensed FINRA member, and Digital Offering LLC, a next-generation investment bank focused on technology and innovation and helping high-quality private and public growth companies access U.S. capital markets.
“We are delighted to launch our capital raise with such an experienced investment banking team who share our vision to democratize our offering to a broad investment pool,” said Michael Chermak, Executive Chairman of Reticulate Micro.
Reticulate will utilize the DealMaker platform which allows the public to invest directly in Reticulate’s stock: https://invest.reticulate.io
The Company plans to use the proceeds from the Reg A Offering to scale sales and marketing as well as operations, invest in new product development, and expand its IP portfolio.
“We are excited to leverage the funds from our Reg A Offering to accelerate the development and delivery of our cutting-edge VAST™ video compression technology, ensuring we stay at the forefront of innovation in national security, healthcare, and critical infrastructure,” said Joshua Cryer, President and CEO of Reticulate Micro.
Investors can receive additional information on the offering either on Reticulate’s investor page at https://reticulate.io/investors/ or via email at ir@reticulate.io.
About Reticulate Micro, Inc.
Reticulate Micro, Inc., with headquarters in Palm Bay, Florida, is a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment. Reticulate is building one of the world’s first post-quantum-encrypted open-systems platforms for robust video streaming, simplified terminal management and satellite mobile connectivity in austere environments and diverse orbital regimes.?Serving the defense, mobility, broadcasting, enterprise infrastructure monitoring and security sectors, Reticulate Micro and its newest business segment Reticulate Space embrace open standards across its software and product offerings.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements that are subject to various risks and uncertainties. In addition, our representatives or we may make forward-looking statements orally or in writing from time to time. We base these forward-looking statements on our expectations and projections about future events, which we derive from the available information. Such forward-looking statements relate to future events or our future performance, including our financial performance and projections, revenue and earnings growth, and business prospects and opportunities. You can identify forward-looking statements by those that are not historical facts, particularly those that use terminology such as “intends,” “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.
Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Company does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by the Company are highly speculative. Investing in shares of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on the Company, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
Contact:
Media:
Reticulate Micro Media Relations
media@reticulate.io
Investor Relations:
Reticulate Micro Investor Relations
$CYCA Reticulate Micro Launches $10M Reg A Capital Raise
Link: https://reticulate.io/reticulate-micro-launches-10m-reg-a-capital-raise/
Digital Offering Allows Defense Tech Provider to Democratize its Offering to Public Investors
PALM BAY, Fla. / August 1, 2024 / Reticulate Micro, Inc. (“Reticulate Micro,” “Reticulate” or the “Company”), a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, has launched its Regulation A stock offering to raise up to $10 million (the “Reg A Offering”) to support Reticulate’s product and market launch efforts as a leading provider of video compression and tactical and SATCOM management solutions. Its flagship product, VAST™, is designed to enable ultra-efficient streaming video and situational awareness in bandwidth-challenged environments.
Reticulate’s offering was qualified with the Securities and Exchange Commission (“SEC”) this week and allows anyone to now invest in the Company. The Reg A Offering has an offering price of $3.50 per unit. Each unit includes one share of the Company’s Class A Common Stock and one warrant to purchase one share of the Company’s Class A Common Stock at an exercise price of $5.50 per share. The minimum investment is $700 for 200 units and is open to all investors.
The lead selling agents for the transaction include Boustead Securities, LLC, a leading full-service investment banking firm and licensed FINRA member, and Digital Offering LLC, a next-generation investment bank focused on technology and innovation and helping high-quality private and public growth companies access U.S. capital markets.
“We are delighted to launch our capital raise with such an experienced investment banking team who share our vision to democratize our offering to a broad investment pool,” said Michael Chermak, Executive Chairman of Reticulate Micro.
Reticulate will utilize the DealMaker platform which allows the public to invest directly in Reticulate’s stock: https://invest.reticulate.io
The Company plans to use the proceeds from the Reg A Offering to scale sales and marketing as well as operations, invest in new product development, and expand its IP portfolio.
“We are excited to leverage the funds from our Reg A Offering to accelerate the development and delivery of our cutting-edge VAST™ video compression technology, ensuring we stay at the forefront of innovation in national security, healthcare, and critical infrastructure,” said Joshua Cryer, President and CEO of Reticulate Micro.
Investors can receive additional information on the offering either on Reticulate’s investor page at https://reticulate.io/investors/ or via email at ir@reticulate.io.
About Reticulate Micro, Inc.
Reticulate Micro, Inc., with headquarters in Palm Bay, Florida, is a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment. Reticulate is building one of the world’s first post-quantum-encrypted open-systems platforms for robust video streaming, simplified terminal management and satellite mobile connectivity in austere environments and diverse orbital regimes.?Serving the defense, mobility, broadcasting, enterprise infrastructure monitoring and security sectors, Reticulate Micro and its newest business segment Reticulate Space embrace open standards across its software and product offerings.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements that are subject to various risks and uncertainties. In addition, our representatives or we may make forward-looking statements orally or in writing from time to time. We base these forward-looking statements on our expectations and projections about future events, which we derive from the available information. Such forward-looking statements relate to future events or our future performance, including our financial performance and projections, revenue and earnings growth, and business prospects and opportunities. You can identify forward-looking statements by those that are not historical facts, particularly those that use terminology such as “intends,” “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.
Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Company does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by the Company are highly speculative. Investing in shares of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on the Company, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
Contact:
Media:
Reticulate Micro Media Relations
media@reticulate.io
Investor Relations:
Reticulate Micro Investor Relations
$CETX News: Cemtrex to Host Fiscal Third Quarter 2024 Financial Results Conference Call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern Time
Hauppauge, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss its results for the fiscal third quarter ended June 30, 2024. A press release detailing these results will be issued prior to the call.
Cemtrex Chief Executive Officer Saagar Govil and Chief Financial Officer Paul Wyckoff will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
Date: Wednesday, August 14, 2024
Time: 5:00 p.m. Eastern time, 2:00 p.m. Pacific time
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 1123331
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1684288&tp_key=6a1e8a9870 and via the investor relations section of the Company's website at www.cemtrex.com.
A replay of the conference call will be available after 8:00 p.m. Eastern time through August 28, 2024.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1123331
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit http://www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit http://www.ais-york.com
For more information visit http://www.cemtrex.com.
https://www.globenewswire.com/newsroom/ti?nf=OTIwMjIyNyM2NDE2NzI5IzIwNDk3MDg=
https://ml.globenewswire.com/media/Yjk4NjU3ZjYtODYyYy00OWE3LThmOWQtODAxMWIxZWMwYzJlLTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.